Wednesday 22 August 2018

Antipsychotic Drugs Market Segments, Opportunity, Growth and Forecast by End-use Industry, Key Competitors and Market value 2018

Market Scenario: 
Psychosis are a group of disorders with serious distortion of thought, behavior, recognition of reality and perception. The patient may have delusions and hallucinations and may have misperception and wrong evaluation of situation, facts or other people.
The most critical market driving factor for anti-psychotic drugs is the rising cases of psychosis and mental disorders. Following are some estimates about psychosis according to the World Health Organization (WHO):
Depression affects an estimated 300 million people in the world.
Bipolar affective disorder takes a toll on about 60 million people worldwide.
Schizophrenia, a severe mental disorder, affects about 21 million people worldwide.
Dementia has a prevalence in about 47.5 million people worldwide
One fourth of people are affected by mental or neurological disorders at some point in their lives.
The current number of untapped patients are of an order of around 450 million currently suffering from such conditions. 


The treatment scenario is no different and the least it is said the better. According to WHO, the gap between the unmet needs in low- and middle-income countries is between 76% and 85% of people with mental disorders. Even in high-income countries the unmet medical needs gap is of an order of 35% and 50% of people with mental disorders. Thus there exists a huge market with unmet medical needs which needs to be tapped. Other very important market driving factor is increasing focus of governments and health care organizations on mental health. For example, WHO's initiated its Mental Health Gap Action Programme in 2008, to expand the coverage of mental health treatment and service across the world.
However there are huge formidable barriers which remain a challenge to expand the market and the anti-psychotic drugs market has shown growth par below their potential market due to a host of factors. The critical market restraint is the poor efficiency and efficacy of anti-psychotic drugs. The side effects of these drugs is another depressing story to tell, which ranges from insomnia, drowsiness, vomiting to the high addiction rate. Social stigma also constraints the market with an estimated two-thirds of patients never seeking help. The poor drug development pipeline is a future market threat. The drug pipeline for anti-psychotics is devoid of any novel acting drug candidate. Strict regulatory framework is another deterrent for companies developing anti-psychotics.
The global market for antipsychotic drugs is expected to reach around USD 18.5 billion by the end of the forecast period and is expected to grow at a CAGR of ~4.3%.
Key Players for Global Antipsychotic Drugs Market:
Some of the key players in this market are: Eli Lilly & Co., Bristol-Myers Squibb, AstraZeneca, Pfizer inc., GlaxoSmithKline plc., Johnson & Johnson  and others.
Segments:
Global antipsychotic drugs market has been segmented on the basis of therapeutic applications, which comprises schizophrenia, bipolar disorder, depression, dementia and others. On the basis of generations; market is segmented into first, second and third.
Regional Analysis of Global Antipsychotic Drugs Market:
Globally America is the largest market for antipsychotic Drugs. The American market for antipsychotic drugs represents about 47 % of world market in 2016. Rapid uptake of new drug molecules and excellent reimbursements scenario in the U.S. are the two most important factors for the dominance of America. Europe is the second-largest market for antipsychotic drugs. Asia pacific region is expected to be fastest growing region in antipsychotic drugs market.

Detailed Table of Contents:
1 Introduction
1.1 Definition
1.2 Scope Of Study
1.3 Research Objective
1.4 Assumptions & Limitations
1.5 Market Structure:
2 Research Methodology
2.1 Research Process
2.2 Primary Research
2.3 Secondary Research
3 Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
3.5 Macroeconomic Indicators
...Continued

         
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Asia-Pacific Glaucoma Treatment Market Volume Forecast and Value Chain Analysis 2018

Market Scenario:
Glaucoma is a disease characterized by fluid builds up in the front part of your eye which results in damages to the eye’s optic nerve which may lead to blindness if left untreated. Open angle glaucoma (OAG) is the most common type of glaucoma followed by closed angle glaucoma (CAG) and these two account for greater than 50% of glaucoma cases. According to World Health Organization (WHO) estimates, Glaucoma is the second most common cause of blindness worldwide after cataract. 

The market for glaucoma is increasing at an impressive rate primarily driven by the growing number of geriatrics. Older population has higher risk of developing glaucoma although other age groups may be affected. Other high risk groups include diabetics and those with a family history of glaucoma. The other market driving factors are increasing awareness, growing healthcare expenditure and screening etc.
The product development strategies have been very impressive with the surgery option. The last decade has seen impressive additions to the surgery options such as laser therapy, photodynamic therapy etc. The market constraints are excellent efficacy and efficiency of present drugs especially prostaglandin analogs and carbonic anhydrase inhibitors, which has set the bar for a new therapy extremely high and the loss of patent protection on the major drugs used to treat glaucoma.
Taking all factors into consideration, we expect the Asia Pacific glaucoma treatment market to reach around $ 888.94 million in 2023 from $576.0 million in 2017, by the end of the forecast period at a CAGR of ~ 7.5 %. While the glaucoma drug market will grow by a flat CAGR of 2.1% the glaucoma surgery market is poised for an explosive CAGR of 18.5 %.
Key Players for Asia-Pacific Glaucoma Treatment Market:
Some of the key players in this market are: Novartis AG, Pfizer Inc., Allergan, Merck & Co., Ocular Therapeutix Inc, pSivida Corp, Icon Bioscience Inc, Amorphex Therapeutics LLC., Ellex, Quantel, Lumenis, and Lightmed among others.
Segments:
Asia-Pacific Glaucoma Treatment Market has been segmented on the basis of disease indication which comprises Closed Angle Glaucoma (CAG), open angle glaucoma (OAG), secondary glaucoma, congenital glaucoma and other. On the basis of drug class; market is segmented into prostaglandin analogs (PGAS), alpha agonist, beta blockers, cholinergic drugs, carbonic anhydrase inhibitors, and others. On the basis of surgery; market is segmented into laser iridotomy, laser trabeculoplasty, aqueous shunt surgery and peripheral iridectomy. On the basis of end users; market is segmented into hospitals and home users.
Regional Analysis of Asia-Pacific Glaucoma Treatment Market:
The healthcare sector of Asia Pacific varies immensely by countries. However the Asia Pacific region has lower public sector expenditure and most treatments involve out of pocket expenditure. Further the eye care has been a neglected segment especially in the poor countries of Asia Pacific region. Japan and South Korea are the leading markets while China will be the fastest growing due to rising healthcare expenditure and faster economic growth. Also the presence of strong generics especially in nations like India will lead to volume growth of anti-glaucoma drugs. The surgery market however will see fastest growth in Japan as compared to developing parts of Asia Pacific.

Detailed Table of Contents:
1 Introduction
1.1 Definition
1.2 Scope Of Study
1.3 Research Objective
1.4 Assumptions & Limitations
1.5 Market Structure:
2 Research Methodology
2.1 Research Process
2.2 Primary Research
2.3 Secondary Research
3 Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
3.5 Macroeconomic Indicators
List Of Tables
Table 1 Asia-Pacific Glaucoma Treatment Market, 2013-2022 (Usd Million)
Table 2 Asia-Pacific Glaucoma Treatment Market, By Disease Indication, 2013-2022 (Usd Million)
Table 3 Asia-Pacific Glaucoma Treatment Market, By Drug Class, 2013-2022 (Usd Million)
Table 4 Asia-Pacific Glaucoma Treatment Market, By Surgery, 2013-2022 (Usd Million)
Table 5 Asia-Pacific Glaucoma Treatment Market, By End Users, 2013-2022 (Usd Million)
Table 6 Asia-Pacific Glaucoma Treatment Market, By Region, 2013-2022 (Usd Million)
List Of Figures
Figure 1 Research Process
Figure 2 Porters Five Forces Model
Figure 3 Asia-Pacific Glaucoma Treatment Market, By Disease Indication
Figure 4 Asia-Pacific Glaucoma Treatment Market, By Drug Class
Figure 5 Asia-Pacific Glaucoma Treatment Market, By Surgery
Figure 6 Asia-Pacific Glaucoma Treatment Market, By End Users
Figure 7 Asia-Pacific Glaucoma Treatment Market, By Region
Figure 8 Asia-Pacific Glaucoma Treatment Market: Company Share Analysis, 2015 (%)
...Continued

         
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Tuesday 21 August 2018

Anesthesia Machine Market Competitive landscape By 2023

Market Scenario:
The anesthetic machine is used to deliver and support anesthesia under the direct supervision of anaesthesiologists. The global anesthetic machine market was valued at 9.4 billion in 2016 and which is expected to reach 14.75 billion at a CAGR of 7.8 during the forecast period of 2016 to 2023.
These figures swell when we include other specialties such as trauma and gynecology, which are capturing a broader market. Advancements in anesthesia system technology and the shift away from general anesthesia towards partial anesthesia, coupled with the development of short-acting anesthetics is driving a change in trend. Thus, the predominant continuous flow anesthetic machine or Boyles anesthesia machine is giving way to the intermittent flow anesthetic machine. Another trend catching on is the growing use of computer controlled anesthesia and patient monitoring devices.
Portability and miniaturization have led to growing adoption of anesthesia in point of care surgeries. The growing capabilities of anesthetic devices such as the ability to deliver variable flow, minimum low flow rate, scavenging systems to capture waste gases, emergency systems such as oxygen flush systems and others are driving the market.
The market restraints of the anaesthetic market are the high cost of installation and maintenance, scarcity of anesthesiologists, the risk of infection, complications such as pain, and deaths due to overdose and others. The mortality rate for general anesthesia is 1:10,000 as cited by many studies. Thus, advancements in devices due to safety concerns is strongly correlated with market growth.
Regional analysis
North America commands the most significant share of the market due to a large number of surgeries and sizeable public expenditure on healthcare. The U.S. spends a substantial proportion of the GDP on healthcare, of which approximately 16 % in 2016. However, the recent reimbursement cuts by the government of U.S. may hinder the market.
Europe market is dominated by Germany, France, and the U.K. Owing to the extensive medical device industry of Germany. Poland, Spain, and Italy also have a sizable market share of the European market.
Asia Pacific region is expected to demonstrate the fastest growth for the anesthesia machine market is owing to economic development and developing healthcare infrastructure. China is expected to drive a considerable growth followed by India. The leading domestic players, in China, are Tuoren Medical, Shengguang Medical, and Qiangjian Medical, which account for approximately 16 % of the local market share of China.
The Middle East and Africa are led by Gulf economies of Saudi Arabia, UAE, Kuwait, and Qatar. The Middle East is a market to watch owing to its high wealth and the development of large hospital complexes in the region such as the King Fahd hospital, Riyadh. The market is however dependent on petrodollar and the expat population, which is a threat to its stability. The kingdom of Saudi Arabia reduced its healthcare spending by 35 percent in the year 2016 to wean the downfall of revenues owing to falling crude oil prices. Saudi Arabia and other Gulf nations spend approximately 75 % of total healthcare expenditure through public budgets which must be seen as a threat as well as opportunity for the private players to capture the domestic market of Gulf economies.
Thus, the short-term prospects for the Middle East region are expected to rise to previous levels after 2018. The government is undertaking harsh fiscal adjustment owing to weak oil price. However, the high and satisfactory foreign reserves of Saudi Arabia, which equal over 95 % of GDP, and low public debt stock of just 5.8 % of GDP in 2015 are enough to say that the cuts will not be too drastic!
The Latin America market is characterized by poor domestic capacity and capability of production. China is expected to increase its share of the medical devices imports of Brazil, especially in low-end devices. Among the regions of Brazil, São Paulo, Minas Gerais, Bahia, Rio de Janeiro and Parana tops the healthcare expenditure list. However, the differential regional healthcare availability owing to extreme social and economic differentiation of the Brazilian population is the prime threat to the market. The inadequate health care in its vast rural areas, political turmoil, the weak Brazilian Real are the other threats to the market.
Competitive Landscape
Heyer Medical AG, Fisher & Paykel Healthcare, Koninklijke Philips N.V, Draeger, GE Healthcare, Covidien, Smiths Medical, Mindray DS USA Inc., and Teleflex Inc.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Monday 20 August 2018

Smoking Cessation And Nicotine De-Addiction Market 2018 Global Analysis, Growth, Size, Share, Trends, Forecast to 2023


Market Scenario
Smoking cessation and nicotine de-addiction are drugs and therapies used in the treatment of withdrawal symptoms associated with the cessation of nicotine. According to the World Health Organization tobacco kills around 6 million people each year and of these almost 5 million deaths are the result of direct tobacco use and approximately 600,000 are the result of passive smoking. Tobacco also derives its users of income, raises healthcare cost and hinder economic development.
Nicotine use also is a risk factor for many diseases and disorders such as cardiovascular diseases, cancer etc. Green tobacco sickness, caused by nicotine absorption through the skin by the handling of wet tobacco leaves in tobacco industry is also a concern especially among children. Tobacco quitting assistance in the form of national cessation services with cost-coverage are available in only 24 countries, representing 15% of the world's population. Only 42 countries, representing 19% of the world's population, have instituted advertisement regulations such as pictorial warnings.
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/2737
The other market driving factors include increasing desire and drives to quit smoking and active role of social and health organizations against tobacco use, the prohibitive costs due to high taxes leveraged on tobacco products, social stigma imposed on tobacco users etc. The other critical market driving factor is the huge number of unmet needs. The World Health Organization (WHO), estimates around 1,100 million smokers worldwide with emerging economies accounting for around 70% of the global smoker population.
The market trends include development of better products such as nicotine gums and patches, e-cigarette’s etc.
The market for Middle East and Africa smoking cessation and nicotine de-addiction was estimated to be around $ 1040 million in 2016. Taking all factors into consideration, we expect the Middle East and Africa smoking cessation and nicotine de-addiction market to reach around $ 2108.38 million, by 2022 growing at a CAGR of 12.5%.
Key Players of Middle East and Africa Smoking Cessation and Nicotine De-Addiction Market
Some of the key players in this market are Pfizer Inc, VMR Products LLC, Johnson & Johnson, Novartis International AG, Cipla Inc., and GlaxoSmithKline plc. Nicotek LLC., and Lorillard, Inc. and others.

Segments:
Middle East and Africa smoking cessation and nicotine de-addiction products market has been segmented on the basis of treatment which comprises of pharmacological, therapies etc. On the basis of product type; market is segmented into drugs, inhalers, patches, sprays and gums and others. On the basis of distribution channels; market is segmented into pharmacies, online and de-addiction centers.

Regional Analysis of Middle East and Africa Smoking Cessation and Nicotine De-Addiction Market
UAE is the largest market in the entire Middle East and Africa smoking cessation and nicotine de-addiction products market closely followed by Egypt. Algeria and South Africa followed by Ethiopia are fastest growing markets in Africa. The rest of Africa market however has maximum population with unmet medical needs.

Apply for Exclusive Discount @ https://www.marketresearchfuture.com/check-discount/2737
Table Of Content
1. Report Prologue
2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
5. Market Factor Analysis
5.1 Porters Five Forces Analysis
5.1.1 Bargaining Power Of Suppliers
5.1.2 Bargaining Power Of Buyers
5.1.3 Threat Of New Entrants
5.1.4 Threat Of Substitutes
5.1.5 Intensity Of Rivalry
Send An Enquiry @  https://www.marketresearchfuture.com/enquiry/2737


About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Posted by at No comments:

Global Biological Computers Market Analysis 2018 Forecasts to 2023

Market Synopsis of the Global Biological computers Market
Biological computers, also known as DNA computers, are microcomputers designed for their use in the field of medicine. This implantable device can be used for various functions such as monitoring the activities of the body or inducing therapeutic effects. Hardware, software, input, and output are the four major components of a biological computer. These components are made of DNA, RNA and proteins. Biological computers are able to perform mathematical calculations that enable the researcher to construct a system of biosensors. This system of biosensors can detect or target specific types of cells such as cancer cells in the patient’s body.
Rising prevalence of cancer, and increasing demand for DNA or gene chips are some of the major factors driving the growth of this market across the globe. Furthermore, increasing healthcare expenditure and overall growth of the healthcare industry also influence the market growth. Splendid research in the field of oncology also boosts the market.
As per the report of the Centers for Disease Control and Prevention (CDC), in 2014, over 14.1 million of new cancer cases were registered worldwide.
The global biological computers market is expected to grow at a CAGR of 7.1% during the forecast period 2017-2023.
Segments                                                                                                                                            
The global biological computers market is segmented on the basis of component, application, and end user.
On the basis of the component, market is segmented into hardware, software, input, and output.
On the basis of the application, the market is segmented into oncology, molecular genetics, nanobiotechnology, and others.
On the basis of the end user, the market is segmented into pharmaceutical & biotechnology companies, research centers, healthcare it companies, hospital & clinics, and others.
Regional Analysis of the Global Biological Computers Market            
The Americas hold the first position in the biological computers market owing to the rising prevalence of cancer in the U.S., and increasing demand for new cancer diagnostic and treatment services. In the Americas, North America is the largest market owing to the presence of key players in the healthcare IT industry.
Europe is the second largest market for biological computers. In Europe, there is an increasing demand for healthcare IT solutions and extensive research and development activities is taking place by clinical research and academic institutes for cancer treatment. According to Cancer Research UK, in 2014, 356,860 new cases of cancer were reported, including 579 cases of bone cancer.  
The market in Asia Pacific is expected to grow at the fastest pace and is driven by the high prevalence of chronic disease such as cancer, obesity, diabetes and other. India, China, and Japan are major contributors to the growth of the market. This growth is attributed to an increasing demand for technologically advanced medical devices and accessories such as gene chips for research activities. Availability of highly qualified medical professionals dedicated to research in biological systems is also a contributing factor. The various other factors affecting the growth of the market in Asia Pacific are rising geriatric population, demand for advanced therapies, government initiatives, and increasing public awareness about various diseases and the available treatments.
Additionally, healthcare spending in Asia Pacific expanded in 2016 due to an extension of state healthcare programs, and the increasing affluence of the population. Organization for Economic Co-operation and Development (ECOD) stated that growth in India will remain high at 7.3% in 2017.
The Middle East & Africa also show a steady rise in the market owing to low technological penetration and increasing awareness about cancer treatment. In the Middle East & Africa, Middle East captures the largest market share for biological medicines owing to the availability of better healthcare infrastructure and wide scope for research.
Key Players in the Global Biological computers Market          
Some of the key players in this market are Microsoft (U.S.), IBM (U.S.), Thermofisher Scientific (U.S.), Illumina, Inc. (U.S.), IndieBio (U.S.), Emulate Inc. (U.S.), and others. Key players manufactruing DNA or gene chips are Sequenom Inc., Merck KGaA (U.S.), Macrogen Corp (Republic of Korea), Bioneer Corporation (Republic of Korea), Biometrix Technology Inc (U.S.), Wafergen Biosystems Inc. (U.S.), and Eurofins Genomics India Pvt Ltd. (India).
Apply for Exclusive Discount @

Detailed Table of Contents:
Table Of Content
  1. Report Prologue
  2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
  1. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
  1. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
...Continued

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Cardiac surgery Instruments Market Dynamics, Forecast, Analysis and Supply Demand 2018

Market Scenario:
Cardiac surgery instruments are specially designed tools that are being used for performing specific actions during the heart related surgery or operation to derive desirable effect. These tools are designed according to use of it, some surgical instruments are used in general surgery while some are designed for specific surgery or operation. Increasing number of heart diseases and cardiac surgery are driving the growth for cardiac surgery instruments market. Growing healthcare sector and increasing number of hospitals are key drivers for the market. Surgical instruments manufacturers are developing new and innovative tools for the market. These instruments are essential for all the hospitals and one of the essential growth factor for the market. Cardiac surgery instrument market is growing moderately. The global Cardiac surgery instruments market in 2015 was about US$ 1.1 billion and expected to reach US$ 1.75 billion at CAGR of 6.9% by 2023.
Market Dynamics:
Increasing Number Of Cardiac Surgeries Is The Prime Driver Of The Market Growth
Increasing number of heart diseases and cardiac surgery, growing healthcare sector and increasing number of hospitals is the prime driver of the market. According to the World Health Organization estimates, in 2015 alone over 17.7 million people representing 31% of all global deaths expired due to complications arising due to cardiovascular diseases. The World Health Organization further states that 82% of the total deaths occurred were in the low- and middle-income countries. Additionally, the Centers for Disease Control and Prevention have said that in 2015, over 630,000 Americans died from heart disease-related issues, resulting in 1 in every 4 deaths.
Favorable Reimbursement Policies Coupled With The Growth In Risk Factors Will Drive A Significant Demand
Other drivers of the market are favorable reimbursement policies, increasing the prevalence of cardiovascular diseases and rising healthcare expenditure are constraining the market. The growth in risk factors such as increasing geriatric and diabetes population, sedentary lifestyles, high intake of fat-rich foods and others are indirectly driving the market. In the latest study conducted by World Health Organization, approximately 422 million people had diabetes in 2015. As per the National Diabetes Statistics Report suggested by Centres for Disease Control and Prevention, it is found that 9.4% of the U.S. population, i.e. 30.3 million people had diabetes in 2015.
Growing Stringency Of Regulations May Hamper The Market
The growing stringency of FDA regulations and uncertainty of healthcare policies in the U.S are significant constraints on the market. The poor per capita income of the underdeveloped economies of the world and the poor healthcare expenditure are dragging the market.
Dominant Players:                                
Some of the key players operating in the market are Johnson & Johnson Services, Inc. (US), DEALMED MEDICAL SUPPLIES LLC (US), Stryker (US), B. Braun Melsungen AG (Germany), STILLE (Sweden),  MedServ International (Germany), Delacroix-Chevalier (France), SIM Surgical (US), Gebrüder Martin GmbH & Co. KG (Germany), Surtex Instruments Limited (UK) and others.
Segments:                                                                                                                                        
To generate an accurate assessment of the global cardiac surgery Instruments market, the report is segmented by type
Based on the type, the market is segmented by forceps, graspers, clamps, scissors, retractors, spreaders, graspers, and others. Based on application, the market is segmented by coronary artery bypass grafting (CABG), valve repair or replacement, aneurysm repair, heart transplant, and others.
Based on the type of material, the market is segmented into stainless steel, tungsten carbide, and others. Based on end user market is segmented into hospitals and ambulatory surgery centers. Based on regions, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa.
Table of Contents:
1 Report Prologue
2 Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
2.3 Market Structure
2.4. Market Segmentation
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
3.5 Forecast Model
List of Tables and Figures:
List Of Tables
Table 1 Global Cardiac Surgery Instruments Market, By Type
Table 2 Global Cardiac Surgery Instruments Market, By Application
Table 3 Global Cardiac Surgery Instruments Market, By Type Of Material
Table 4 Global Cardiac Surgery Instruments Market, By End User
Table 5 Global Cardiac Surgery Instruments Market, By Region
List Of Figures
Figure 1 Research Process
Figure 2 Porters Five Forces Model
Figure 3 Global Cardiac Surgery Instruments Market, By Type
Figure 4 Global Cardiac Surgery Instruments Market, By Application
Figure 5 Global Cardiac Surgery Instruments Market, By Type Of Material
Figure 6 Global Cardiac Surgery Instruments Market, By End User
...Continued

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Current and forthcoming Antipsychotic Drugs Market size in terms of volume and value 2018

Market Scenario: 
Psychosis are a group of disorders with serious distortion of thought, behavior, recognition of reality and perception. The patient may have delusions and hallucinations and may have misperception and wrong evaluation of situation, facts or other people.
The most critical market driving factor for anti-psychotic drugs is the rising cases of psychosis and mental disorders. Following are some estimates about psychosis according to the World Health Organization (WHO):
Depression affects an estimated 300 million people in the world.
Bipolar affective disorder takes a toll on about 60 million people worldwide.
Schizophrenia, a severe mental disorder, affects about 21 million people worldwide.
Dementia has a prevalence in about 47.5 million people worldwide
One fourth of people are affected by mental or neurological disorders at some point in their lives.
The current number of untapped patients are of an order of around 450 million currently suffering from such conditions. 
The treatment scenario is no different and the least it is said the better. According to WHO, the gap between the unmet needs in low- and middle-income countries is between 76% and 85% of people with mental disorders. Even in high-income countries the unmet medical needs gap is of an order of 35% and 50% of people with mental disorders. Thus there exists a huge market with unmet medical needs which needs to be tapped. Other very important market driving factor is increasing focus of governments and health care organizations on mental health. For example, WHO's initiated its Mental Health Gap Action Programme in 2008, to expand the coverage of mental health treatment and service across the world.
However there are huge formidable barriers which remain a challenge to expand the market and the anti-psychotic drugs market has shown growth par below their potential market due to a host of factors. The critical market restraint is the poor efficiency and efficacy of anti-psychotic drugs. The side effects of these drugs is another depressing story to tell, which ranges from insomnia, drowsiness, vomiting to the high addiction rate. Social stigma also constraints the market with an estimated two-thirds of patients never seeking help. The poor drug development pipeline is a future market threat. The drug pipeline for anti-psychotics is devoid of any novel acting drug candidate. Strict regulatory framework is another deterrent for companies developing anti-psychotics.
The global market for antipsychotic drugs is expected to reach around USD 18.5 billion by the end of the forecast period and is expected to grow at a CAGR of ~4.3%.
Key Players for Global Antipsychotic Drugs Market:
Some of the key players in this market are: Eli Lilly & Co., Bristol-Myers Squibb, AstraZeneca, Pfizer inc., GlaxoSmithKline plc., Johnson & Johnson  and others.
Segments:
Global antipsychotic drugs market has been segmented on the basis of therapeutic applications, which comprises schizophrenia, bipolar disorder, depression, dementia and others. On the basis of generations; market is segmented into first, second and third.
Regional Analysis of Global Antipsychotic Drugs Market:
Globally America is the largest market for antipsychotic Drugs. The American market for antipsychotic drugs represents about 47 % of world market in 2016. Rapid uptake of new drug molecules and excellent reimbursements scenario in the U.S. are the two most important factors for the dominance of America. Europe is the second-largest market for antipsychotic drugs. Asia pacific region is expected to be fastest growing region in antipsychotic drugs market.
Detailed Table of Contents:
1 Introduction
1.1 Definition
1.2 Scope Of Study
1.3 Research Objective
1.4 Assumptions & Limitations
1.5 Market Structure:
2 Research Methodology
2.1 Research Process
2.2 Primary Research
2.3 Secondary Research
3 Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
3.5 Macroeconomic Indicators
...Continued
     
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels: , ,
Subscribe to: Posts (Atom)